| drug name | Moxifloxacin |
| classification | Fluoroquinolone antibiotic |
| pharmacokinetics | | absorption | Well absorbed orally, with peak plasma concentrations typically reached within 1–2 hours. | | distribution | Distributes widely throughout the body, including the lungs, sinuses, and middle ear. | | metabolism | Metabolized primarily in the liver, with some renal excretion. | | excretion | Excreted in the urine and bile. |
|
| suggested dosage | | adults | | 1 | | dosage form | Oral tablet | | dosage mg | 400 mg | | frequency | Once daily |
|
| | notes | Adjust dosage for patients with renal impairment. Specific dosage for a patient should be determined by a healthcare professional after careful assessment. |
|
| indications | | 1 | Community-acquired pneumonia | | 2 | Sinusitis | | 3 | Skin infections | | 4 | Urinary tract infections | | 5 | Other infections (based on culture results and clinical judgment) |
|
| safety in pregnancy | Limited data available. Should be used during pregnancy only if the potential benefits outweigh the potential risks. Consult with a physician. |
| safety in breastfeeding | May be present in breast milk. Consult with a physician before use. |
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Diarrhea | | 4 | Headache | | 5 | Dizziness | | 6 | Insomnia | | 7 | Peripheral neuropathy (especially with prolonged use or higher doses) | | 8 | Tendinopathy (especially Achilles tendon) | | 9 | Photosensitivity | | 10 | QT prolongation (especially in patients with risk factors) | | 11 | Clostridium difficile-associated diarrhea (C. difficile-associated diarrhea) | | 12 | Hypersensitivity reactions (rash, hives, itching, anaphylaxis) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to moxifloxacin or other fluoroquinolones | | 2 | History of severe tendinopathy or tendon rupture | | 3 | Patients with certain pre-existing cardiac conditions (QT prolongation risk). |
|
| interactions | | 1 | Increased risk of adverse events with concomitant use of certain drugs, including theophylline and medications that can affect the QT interval. | | 2 | May interact with certain medications and supplements. Consult a healthcare professional. |
|
| warnings and precautions | | 1 | Careful monitoring for adverse effects, especially in patients with kidney disease, liver disease, or those taking other medications. | | 2 | Patients should be advised about the potential risk of tendinopathy, especially in those who are taking corticosteroids or who have risk factors for tendon problems. | | 3 | Avoid use in patients with known or suspected myasthenia gravis. | | 4 | Do not use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. |
|
| additional information | Consult a physician for appropriate dosage, duration, and monitoring strategies, especially for long-term use. |
| patient specific considerations | | age | 25 years - appropriate for general adult dosage | | weight | 70 kg - appropriate for general adult dosage |
|
| disclaimer | This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. |
